Fluocinonide
Brand names: Metosyn
Fluocinonide is a potent topical corticosteroid used for steroid-responsive inflammatory dermatoses such as eczema and psoriasis.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It binds glucocorticoid receptors in skin cells to produce anti-inflammatory, immunosuppressive and vasoconstrictive effects.
Prescribing in practice
- Because it is potent, prolonged use, large surface areas, occlusion, or use on the face and flexures increases the risk of skin atrophy and systemic absorption; use the lowest effective potency for the shortest time.
- Reserve potent steroids for thicker or more resistant lesions and step down as the condition improves.
- Avoid application to untreated infected skin.
Monitoring
No routine laboratory monitoring is required; review for treatment response and signs of local steroid-induced skin changes.
Counselling the patient
- Apply a thin layer to affected skin only and avoid the face unless specifically advised.
- Do not use on infected or broken skin without medical advice.
- Keep using emollients alongside the steroid.
Evidence & guidelines
Potent topical corticosteroids are an established option for resistant inflammatory dermatoses, consistent with NICE potency-matched prescribing.
Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD